The Knight ADRC has supported many investigators at Washington University and at other institutions over the years. We wish to avoid the situation where two investigators study the same research question to avoid duplication of effort and potential conflict. To determine if your topic has already been studied with our resources, please search our database. If you find that your topic or a related topic has been submitted, you may wish to contact the investigator to inquire about their findings to determine how you might proceed. You may wish to collaborate or modify your request to avoid overlap. The results below reflect requests made since online requests have been accepted. As such, not all fields will have data as certain information, such as aims, were not collected until recently. If an entry has been assigned an ID number (e.g. T1004), the full request has been submitted and is either approved, disapproved or in process. If an entry has no ID number, then it represents a submission that has not yet been reviewed. Search terms are applied across an entire requests application including variables not displayed below. A more specific, detailed search may yield better results depending upon your needs.
Search Terms:
Investigator: Yue Huang
Project Title: CSF MMP10 as a renal-function–modified marker of cognitive vulnerability in aging and Alzheimer’s disease
Date: May 19, 2026 at 7:44 am
Request ID:
Aim 1: Validate whether CSF MMP10 is associated with baseline cognitive impairment and dementia severity in Knight ADRC participants
Aim 2: Test whether CSF MMP10 predicts longitudinal cognitive decline across memory, global cognition, and CDR-based outcomes.
Aim 3: Examine whether CSF MMP10 is associated with MRI markers of vascular brain injury, including WMH burden and brain atrophy.
Aim 4: Explore whether renal dysfunction or kidney disease history modifies the association of CSF MMP10 with cognitive decline and MRI injury.
Investigator: Takahisa Kanekiyo, M.D., Ph.D
Project Title: Immune activation markers in age-related cognitive decline and Alzheimer’s disease
Date: May 14, 2026 at 9:02 am
Request ID:
Aim 1: alidate CSF biomarker profiles associated with conversion from MCI to dementia, with a focus on inflammatory and AD-related markers that may improve prediction of disease progression beyond established CSF biomarkers.
Aim 2: Validate plasma biomarker signatures associated with progression from cognitively unimpaired status to mild cognitive impairment, focusing on inflammatory and Alzheimer’s disease-related biomarkers that may predict incident MCI among cognitively unimpaired individuals.
Aim 3:
Aim 4:
Investigator: FU XIAOZHOU
Project Title: Construction of a Predictive Model for the Conversion from Cognitive Impairment to Alzheimer’s Disease Based on Multimodal Feature Fusion
Date: May 12, 2026 at 3:42 am
Request ID:
Aim 1: Biomarker Discovery
Aim 2:
Aim 3:
Aim 4:
Investigator: Elham Ghanbarian
Project Title: Inflammation and Non-Amyloid Neurodegeneration in Aging and Alzheimer’s Disease
Date: May 8, 2026 at 11:54 am
Request ID: D2629
Aim 1: To investigate the contribution of non-amyloid neurodegenerative processes to cognitive decline and medial temporal lobe degeneration in aging
Aim 2: To investigate the contribution of systemic inflammation to cognitive decline and medial temporal lobe degeneration in aging
Aim 3: To assess the potential of non-amyloid degeneration processes and systemic inflammation to improve differentiation between Alzheimer’s disease and related pathologies such as LATE
Aim 4:
Investigator: Ruiwen Zhou
Project Title: Dynamic Multimodal Prediction of Alzheimer’s Disease Progression Using Longitudinal Data with Missing-Modality Generative Modeling
Date: May 6, 2026 at 11:29 am
Request ID: D2628
Aim 1: Develop a Longitudinal Multimodal Deep Learning Framework for Dynamic Prediction of Alzheimer’s Disease Progression
Aim 2: Design a Generative Missing-Modality Framework for Longitudinal Multimodal Alzheimer’s Disease Data
Aim 3: Identify Longitudinal Multimodal Biomarkers and Disease Trajectories Associated with Alzheimer’s Disease Progression
Aim 4:
Investigator: Shubham Chandra
Project Title: Virtual Spectral Decomposition of Multiplexed Plasma Biomarkers for Multi-Class Dementia Routing: Extending a Blood-Based Alzheimer’s Disease Signature Framework to FTD, DLB, and Vascular Dementia
Date: May 4, 2026 at 7:56 am
Request ID: D2627
Aim 1: Validate a 4-biomarker VSD framework (pT217, Aβ42/40, NfL, GFAP) developed on ADNI in the Knight ADRC cohort to assess cross-cohort generalizability of AD disease signature coupling patterns and exclusion logic against amyloid PET ground truth.
Aim 2: Identify candidate plasma proteins from the NULISAseq CNS panel that provide differential signal across AD, DLB, FTD, and PD diagnostic groups, to define new VSD channel weights and dendritic branch terminals for multi-class dementia routing.
Aim 3: Characterize biomarker coupling structure within the non-AD neurodegeneration subgroup to determine whether VSD channel activation patterns can discriminate FTD from DLB from vascular contributions using expanded protein panels.
Aim 4: Evaluate longitudinal stability of VSD-derived disease route assignments across repeated plasma draws to assess whether routing classifications track with clinical progression or remain static at baseline assignment.
Investigator: Carlos Cruchaga
Project Title: Transcriptomics and multiomic predictive models in AD and ADRD
Date: May 4, 2026 at 7:21 am
Request ID: D2626
Aim 1: 1. To benchmark the blood circRNA and proteomic models in predicting AD compared to MS tau analytes in CSF and plasma and determine on how the overlap with other biomarkers.
Aim 2: Pathways and cell type enrichment of the transcripts and proteins associated with AD phenotypes (risk, onset, progression) or endophenotypes (AD biomarker levels).
Aim 3: Integrating the MS proteomic data with the rest of the omic data to further refine the AI-derived model.
Aim 4:
Investigator: Pieter Jelle Visser and Willemijn Jansen
Project Title: Early diagnosis of Alzheimer’s disease: insight into p-tau217 as a new blood-based biomarker
Date: May 1, 2026 at 4:15 am
Request ID: D2625
Aim 1: We aim to gain more insight into the prevalence of plasma p-tau217 abnormality across the continuum of AD (NC/SCD/MCI/AD), dependent on age, APOEe4 status, sex, education level, comorbidities, and diagnosis.
Aim 2: We aim to investigate differences in the prevalence of plasma p-tau217 positivity in and between different ethnic groups.
Aim 3: We aim to investigate how plasma p-tau217 levels relate to cognitive function and decline over time.
Aim 4: We aim to compare the predictive ability of plasma p-tau217 with other plasma, PET and CSF biomarkers, such as other p-tau species, NFL and GFAP.
Investigator: Guoyan Zhao
Project Title: Elucidating shared vascular mechanisms of neurodegeneration through uniform single-nucleus RNA transcriptomic analysis
Date: April 28, 2026 at 12:09 am
Request ID: D2624
Aim 1: Delineate vascular cell-specific transcriptomic changes across five NDDs and five brain regions
Aim 2: Identify candidate drugs through consensus in silico screening.
Aim 3:
Aim 4:
Investigator: Suprateek Kundu
Project Title: Multimodal Biomarker Approaches for Risk Stratification and Screening in Alzheimer’s Disease
Date: April 25, 2026 at 1:09 pm
Request ID: D2623
Aim 1: To integrate baseline blood-based biomarkers with regional longitudinal structural brain atrophy changes, to predict future cognitive decline in cognitively unimpaired individuals, and infer significant interactions between regional neurodegeneration and p-tau217.
Aim 2: To integrate baseline blood-based biomarkers with regional longitudinal white matter hyperintensity (WMH) changes, to predict future cognitive decline in cognitively unimpaired individuals, and infer significant interactions between regional WMH and p-tau217.
Aim 3: To forecast future neurodegeneration in cognitively unimpaired individuals, by predicting long term brain atrophy and white matter hyperintensity changes based on longitudinal imaging data from earlier visits.
Aim 4: